Aleafia Health Inc ALEAF

RE:RE:RE:RE:RE:RE:RE:RE:RE:Nice to see Vivo

[Schaffhausen]

stocktracker101 wrote: I didnt notice the news release on the debentures.. That leaves them with very little cash. Approx 10 million cash minus expenses + revenue for the quarter (q3). Either way, I agree that they most likely don't make it. Maybe Aleafia can make a deal for their patients...

christophwaltz wrote: Vivo already moved on the debentures, but it still leaves them wanting for cash, hence the failed/stopped raise attempt: https://www.newswire.ca/news-releases/vivo-cannabis-tm-completes-debenture-refinancing-879549556.html

Of the original $22,600,000 in debentures, Vivo paid some with $10.5M cash, converted some to 32,800,000 shares, and still owe $6,600,000 in debs.

They need money now if they are to survive. Likely they don't make it.

Hey All, Vivo should have all necessary cash resource to get through Q3 2021 (mgmt prospectus Oct.6), but this seems the worst case scenario. Truth is that VIVO may be the first of the small LP cohort to be cash flow positive, and this is expected by H1 2021. See for yourselves, have a look at the Q2 financials for burn rate, consider the revenue growth rate that is equal to any of the cohort and going forward from mid-Oct VIVO has the leanest cost structure of all peers after making recent streamlining decisions, decisions that other companies will also have to come to terms with soon. Innovative Airhouses allow for top grade Cultivation for a longer grow season at lower cost than indoor....although I admit I like Aleafia outdoor grow success which will be great once the market demands all that production. VIVO having the lions share of the concentrates market (58% OSC) and a strong pharma presence positions VIVO well. VIVO MGMT have no capital market clout or savvy which has battered the SP, however, the business couldn't be more sound. Cheers, Schaff